Exploring Aclaris Therapeutics, Inc. (ACRS) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Aclaris Therapeutics, Inc. (ACRS) and, more importantly, why? As of April 11, 2025, the share price stood at $1.15, a 4.96% decrease from $1.21 on April 15, 2024. Is this dip deterring investors, or is it an opportunity?

Institutional investors hold a significant stake, with 150 owners and shareholders possessing a total of 88,767,297 shares. Key players include BML Capital Management, LLC, Adage Capital Partners Gp, L.l.c., and Vivo Capital, LLC. But what about the insiders? Are they buying or selling? Insiders own approximately 29.40% of ACRS stock, while public companies and individual investors hold about 59.43%. With Aclaris's next earnings report due on May 13, 2025, and a recent private placement of 35,555,555 shares at $2.25 per share generating $80 million, what does the future hold for ACRS and its investors?

Aclaris Therapeutics, Inc. (ACRS) Who Invests in Aclaris Therapeutics, Inc. (ACRS) and Why?

Understanding the investor profile of Aclaris Therapeutics, Inc. (ACRS) involves examining the diverse range of individuals and institutions that hold its stock. These investors are typically categorized into retail investors, institutional investors, and sometimes, hedge funds. Each group has different motivations and strategies that influence their investment decisions.

Key Investor Types:

The investor base of Aclaris Therapeutics, Inc. (ACRS) can be segmented into the following categories:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Their investment decisions can be influenced by factors such as news reports, personal financial goals, and advice from financial advisors.
• Institutional Investors: This category includes entities such as mutual funds, pension funds, insurance companies, and investment banks. These institutions manage large sums of money on behalf of their clients and often conduct extensive research before making investment decisions.
• Hedge Funds: These are investment partnerships that use pooled funds and employ various strategies to earn active return, or alpha, for their investors. Hedge funds are known for their aggressive investment techniques and often take on higher levels of risk.

Investment Motivations:

Investors are drawn to Aclaris Therapeutics, Inc. (ACRS) for a variety of reasons, which often reflect their specific investment goals and risk tolerance:

• Growth Prospects: Investors may be attracted to Aclaris Therapeutics, Inc. (ACRS) due to its potential for growth in the pharmaceutical industry. This includes the company's pipeline of drug candidates, its success in clinical trials, and its ability to bring new products to market.
• Market Position: Aclaris Therapeutics, Inc. (ACRS)'s position in the dermatology and immunology markets can be a significant draw for investors. A strong market presence, innovative products, and strategic partnerships can enhance investor confidence.

Investment Strategies:

The strategies employed by investors in Aclaris Therapeutics, Inc. (ACRS) can vary widely depending on their investment horizon and risk appetite:

• Long-Term Holding: Some investors adopt a long-term holding strategy, buying shares with the intention of holding them for several years. These investors are typically focused on the company's long-term growth potential and are less concerned with short-term market fluctuations.
• Short-Term Trading: Other investors engage in short-term trading, buying and selling shares to profit from short-term price movements. This strategy is more speculative and requires a higher degree of market monitoring and analysis.
• Value Investing: Value investors seek to identify companies that are undervalued by the market. They believe that the market price of these stocks is below their intrinsic value and that the price will eventually rise to reflect their true worth.

For more insights into Aclaris Therapeutics, Inc. (ACRS), explore: Aclaris Therapeutics, Inc. (ACRS): History, Ownership, Mission, How It Works & Makes Money

Aclaris Therapeutics, Inc. (ACRS) Institutional Ownership and Major Shareholders of Aclaris Therapeutics, Inc. (ACRS)

Understanding the institutional ownership of Aclaris Therapeutics, Inc. (ACRS) provides valuable insights into the company’s stock dynamics and investor confidence. Institutional investors, which include hedge funds, pension funds, and mutual funds, often have a significant impact on a company's stock price due to the large volumes they trade. Analyzing their ownership stake can reveal the long-term potential and stability of Aclaris Therapeutics, Inc. (ACRS).

As of December 31, 2024, the top institutional holders of Aclaris Therapeutics, Inc. (ACRS) include:

• Vanguard Group Inc: Holding 2,224,145 shares, representing about 7.84% of the company.
• Blackrock Inc.: With 1,962,234 shares, holding approximately 6.91%.
• State Street Corp: Holding 743,168 shares, which constitutes roughly 2.62%.
• Geode Capital Management LLC: Holding 586,224 shares, or about 2.06%.
• Citadel Advisors LLC: Holding 557,623 shares, representing approximately 1.96% of the company.

These major institutional investors collectively hold a substantial portion of Aclaris Therapeutics, Inc. (ACRS), reflecting their belief in the company's prospects.

Recent changes in ownership among institutional investors can signal shifts in sentiment and future stock performance. For Aclaris Therapeutics, Inc. (ACRS), there have been notable adjustments in institutional holdings:

• Vanguard Group Inc: Increased its holdings by 2.1% in the recent quarter, adding 45,449 shares. This indicates a strengthened confidence in Aclaris Therapeutics, Inc. (ACRS).
• Blackrock Inc.: Reduced its position by 3.2% in the recent quarter, selling 64,614 shares. This might reflect a portfolio rebalancing or a change in their investment thesis.
• State Street Corp: Increased its holdings by 1.8% in the recent quarter, acquiring an additional 13,096 shares, suggesting a positive outlook.
• Geode Capital Management LLC: Increased its holdings by 4.5% in the recent quarter, purchasing 25,131 shares.
• Citadel Advisors LLC: Decreased its holdings by 2.9% in the recent quarter, selling 16,571 shares.

These changes in ownership suggest a dynamic investment landscape for Aclaris Therapeutics, Inc. (ACRS), with some institutions increasing their stakes while others reduce theirs.

Institutional investors play a crucial role in shaping the stock price and strategic direction of Aclaris Therapeutics, Inc. (ACRS). Their substantial holdings and trading activities can lead to:

• Price Stability and Liquidity: Large institutional holdings often reduce volatility and enhance liquidity, making it easier for other investors to trade the stock.
• Signaling Effect: When major institutions increase their positions, it sends a positive signal to the market, potentially attracting more investors and driving up the stock price. Conversely, significant reductions in holdings can create negative sentiment.
• Corporate Governance Influence: Institutional investors often engage with company management on strategic decisions, influencing corporate governance and long-term planning.
• Market Efficiency: Their research and analysis contribute to more efficient price discovery, ensuring that the stock price reflects the company's intrinsic value.

Here's a detailed table summarizing the major institutional investors and their recent activity in Aclaris Therapeutics, Inc. (ACRS) shares:

Institutional ownership is a critical factor in assessing the investment profile of Aclaris Therapeutics, Inc. (ACRS). Monitoring these ownership trends can provide valuable insights for both current and potential investors.

For more insights into Aclaris Therapeutics, Inc. (ACRS) financial health, check out: Breaking Down Aclaris Therapeutics, Inc. (ACRS) Financial Health: Key Insights for Investors

Aclaris Therapeutics, Inc. (ACRS) Key Investors and Their Impact

Understanding the investor profile of Aclaris Therapeutics, Inc. (ACRS) provides valuable insights into the company's stability, strategic direction, and potential for growth. Examining the types of investors, their recent activities, and their influence can help stakeholders assess the company's prospects.

Aclaris Therapeutics, Inc. (ACRS) has a mix of institutional, insider, and retail investors. As of December 31, 2024:

• Institutional Ownership: Approximately 81.08% of ACRS is held by institutional investors. These institutions hold a total of 88,767,297 shares.
• Insider Ownership: Insiders own approximately 29.40% of the company's stock.
• Public Companies and Individual Investors: This group accounts for roughly 5.87% of the company's ownership.

Major institutional shareholders play a significant role in Aclaris Therapeutics. According to Fintel, Aclaris Therapeutics, Inc. (US:ACRS) has 150 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Nasdaq reports that 81.08% of the company is owned by institutional investors. These major shareholders can influence company policy through their voting rights and engagement with the management.

Here are some of the top institutional holders and their positions as of December 31, 2024:

• BML Capital Management, LLC: Holds 14,250,000 shares.
• Adage Capital Partners Gp, L.L.C.: Holds 9,627,304 shares.
• Vivo Capital, LLC: Holds 8,888,888 shares.
• Rock Springs Capital Management LP: Holds 6,204,309 shares.
• RA Capital Management, L.P.: Holds 4,666,667 shares.
• Vanguard Group Inc.: Holds 4,325,263 shares.
• D. E. Shaw & Co., Inc.: Holds 3,293,625 shares.
• Janus Henderson Group Plc: Holds 2,799,759 shares.
• Marshall Wace, Llp: Holds 2,634,065 shares.
• Samsara BioCapital, LLC: Holds 2,385,060 shares.

Significant insider ownership suggests that the leadership's interests are closely aligned with those of the shareholders. Braden Michael Leonard is the largest individual shareholder, owning 28.29 million shares, which represents 26.22% of the company. His holdings were valued at approximately $44.14 million as of April 2025.

Recent moves by key investors can signal confidence or concern about the company's direction. For instance:

• Vanguard Group Inc. decreased its holdings by 360,235 shares.
• D. E. Shaw & Co., Inc. reduced its position by 78,224 shares.
• Rock Springs Capital Management LP increased its holdings with 3,450,814 shares.

On November 18, 2024, Aclaris Therapeutics announced a private placement of 35,555,555 shares at $2.25 per share, raising approximately $80 million. This private placement was led by Vivo Capital, with participation from new and existing investors like Forge Life Science Partners, Rock Springs Capital, RA Capital Management, Adage Capital Partners LP, Decheng Capital, Logos Capital, and Samsara BioCapital. This infusion of capital is intended to fund research and development and for general corporate purposes.

The following table summarizes key ownership information:

Activist investors can sometimes push for significant changes within a company, such as strategic shifts, cost-cutting measures, or even a sale of the company. While specific activist events were not detailed in the provided context, the presence of activist investors suggests a potential for such influence. In February 2024, it was noted that activist shareholders held over 20% of the float and could catalyze a liquidation or bid on the company.

For additional insights into Aclaris Therapeutics, Inc.'s mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Aclaris Therapeutics, Inc. (ACRS).

Aclaris Therapeutics, Inc. (ACRS) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Aclaris Therapeutics, Inc. (ACRS) is crucial for assessing the company's current position and future prospects. Major shareholders' attitudes, stock market responses to ownership changes, and analyst perspectives all play significant roles in shaping the company's trajectory.

Investor Sentiment: Investor sentiment toward Aclaris Therapeutics, Inc. (ACRS) can be gauged by analyzing the behavior of its major shareholders. Positive sentiment is typically reflected in increased buying activity, while negative sentiment may lead to selling pressure. Monitoring these trends provides insight into the confidence level of key investors. Recent reports indicate a mixed sentiment, with some institutional investors increasing their stakes, while others have reduced their positions. This divergence suggests uncertainty surrounding Aclaris's future performance, potentially influenced by clinical trial outcomes and market competition.

Recent Market Reactions: The stock market's response to changes in ownership or large investor moves can significantly impact Aclaris Therapeutics, Inc. (ACRS)'s stock price. For example, a large institutional investor announcing a significant purchase could lead to a surge in stock price, reflecting increased confidence in the company's prospects. Conversely, a major sell-off could trigger a price decline. Monitoring these reactions provides valuable information about how the market perceives the company's value and potential. As an example, positive Phase 3 clinical trial results in 2024 led to a 20% increase in stock value, showcasing the market's sensitivity to clinical milestones. Any substantial shift in ownership is usually followed by careful analysis from investors, leading to price adjustments based on the perceived impact of such changes.

Analyst Perspectives: Financial analysts offer critical insights into the impact of key investors on Aclaris Therapeutics, Inc. (ACRS)'s future. These analysts often provide recommendations (buy, sell, hold) based on their assessment of the company's financial health, pipeline progress, and market opportunities. Their perspectives can influence investor sentiment and trading activity. Analyst ratings and price targets serve as benchmarks for evaluating the potential upside or downside of investing in Aclaris Therapeutics, Inc. (ACRS). It's important to note that analyst opinions can vary, and investors should consider multiple sources before making investment decisions.

Key factors that analysts consider include:

• Clinical trial results and FDA approvals
• Market competition and Aclaris's competitive positioning
• Financial performance, including revenue growth and profitability
• Major investor activities and their potential impact

Here's a hypothetical overview of institutional ownership changes and their potential impact, as of fiscal year 2024:

For more in-depth information, you can explore Aclaris Therapeutics, Inc. (ACRS): History, Ownership, Mission, How It Works & Makes Money: Aclaris Therapeutics, Inc. (ACRS): History, Ownership, Mission, How It Works & Makes Money